GlassScriptPhysician profile
Steven M Pounders
NPI 1124073614
$33,060.57
in general payments reported to CMS, 2019-2025
58 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,937 · 2020: $2,031 · 2021: $7,671 · 2022: $5,948 · 2023: $3,500 · 2024: $2,890 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,963 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,962.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,238.26 | 2019-2025 | Sunlenca, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $7,565.76 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Products, LP | $3,056.68 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $3,019.21 | 2019-2025 | Trogarzo, Egrifta |
| Biohaven Pharmaceuticals, INC. | $1,300.97 | 2021 | |
| Merck Sharp & Dohme LLC | $1,251.03 | 2019-2025 | Pifeltro, Delstrigo, Isentress |
| Lilly USA, LLC | $542.14 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Supernus Pharmaceuticals, INC. | $514.65 | 2022-2023 | Qelbree, Xyosted |
| Novo Nordisk INC | $506.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $477.33 | 2019-2025 | |
| Antares Pharma, INC. | $466.70 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $412.01 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $285.10 | 2019-2025 | Serostim |
| Allergan, INC. | $273.43 | 2019-2020 | |
| Napo Pharmaceuticals INC | $250.27 | 2019-2025 | Mytesi |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pounders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.